Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.

Détails

Ressource 1Télécharger: REF.pdf (77.31 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_9FEAE9F52639
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Lettre (letter): communication adressée à l'éditeur.
Collection
Publications
Institution
Titre
Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.
Périodique
Pediatric Nephrology
Auteur⸱e⸱s
Cachat F., Bardy D., Durussel C., Di Paolo E.
ISSN
0931-041X (Print)
ISSN-L
0931-041X
Statut éditorial
Publié
Date de publication
2006
Volume
21
Numéro
2
Pages
301-302
Langue
anglais
Notes
Publication types: Case Reports ; LetterPublication Status: ppublish. PDF type: LETTER TO THE EDITORS
Résumé
Alteplase has been shown to be effective in preventing central venous access clotting in patients on hemodialysis. Because of a high phosphorus content in its excipient, it can inadvertently contaminate blood samples, leading the physician in care of the patient to erroneously increase dialysis time or change diet in order to control the pseudo-hyperphosphatemia.
Mots-clé
Catheterization, Central Venous/instrumentation, Child, Preschool, Fibrinolytic Agents/adverse effects, Humans, Male, Phosphorus Metabolism Disorders/chemically induced, Renal Dialysis/instrumentation, Tissue Plasminogen Activator/adverse effects
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/04/2013 10:28
Dernière modification de la notice
14/02/2022 7:56
Données d'usage